Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia | Immunotherapy
Fostamatinib Disodium Hexahydrate: A Novel Treatment for Adult Immune Thrombocytopenia
Medicina | Free Full-Text | Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms
Favorable aspects and potential difficulties foreseen by the EP with... | Download Scientific Diagram
Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
IJMS | Free Full-Text | Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach
Novel therapies for immune thrombocytopenia - Kuter - 2022 - British Journal of Haematology - Wiley Online Library
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406 | SpringerLink
Mechanism of action: R406 is a Syk kinase inhibitor. a, inhibition of... | Download Scientific Diagram
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy | Nature Reviews Clinical Oncology
g176401moi008.gif
JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
Rigel launches Phase II trial to assess fostamatinib for Covid-19
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib - Nichola Cooper, Ivy Altomare, Mark R. Thomas, Phillip L. R. Nicolson, Steve P. Watson, Vadim Markovtsov, Leslie K. Todd,
Frontiers | Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Recent advances in the mechanisms and treatment of immune thrombocytopenia - eBioMedicine
Mechanism of Action | TAVALISSE HCP
APS Publications on Twitter: "Platelets and tyrosine kinase inhibitors: clinical features, mechanism of action and effects on physiology - new Review in @AJPCellPhys https://t.co/G9SSGG4Hrq #platelets #articlesinpress https://t.co/oJ0JnJMjho" / Twitter
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
R406 besylate | Syk inhibitor - Active metabolite of Fostamatinib | InvivoGen
Mechanism of Action | TAVALISSE HCP
Advances in targeted therapy for malignant lymphoma | Signal Transduction and Targeted Therapy
Rigel's fostamatinib successfully meets endpoint in chronic ITP trial
![PDF] Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5c2330a7e20affaf506ba421407aa70a9a225a24/5-Figure1-1.png "PDF] Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults | Semantic Scholar")